PIMCO Flagship Fund Trims Mag 7 Positions, Pivots to Asian AI Supply Chain
nashnova research
Pimco's $19 billion balanced fund is trimming U.S. mega-cap tech and shifting overweight into Asia's AI supply chain, Chinese financials, and biotech — a signal that one of Wall Street's top-performing shops sees better risk-reward away from the most expensive names.
Why cut the highest-returning Mag 7 names?
Fund manager Emmanuel Sharef said it plainly: Pimco is underweight most Mag 7 stocks and hyperscalers for one reason — valuations are too high.
This means → Pimco is not bearish on AI itself; it believes you can capture the AI theme without owning the priciest tickets.
As AI spending climbs, U.S. mega-cap tech faces rising debt loads and murkier earnings visibility, making the risk-reward less attractive.
Where is the money going — Asia's AI supply chain?
Pimco is now overweight Asia, targeting companies downstream in the AI buildout with strong earnings growth.
In plain terms = building an AI data center requires semiconductors, chips, cooling gear, cables, optical equipment, power units, construction machinery, metals, and rare earths — a huge share of those suppliers sit in Asia.
Sharef specifically flagged Chinese mining and materials firms as key players in data-center construction and rare-earth supply.
Inside China, what is Pimco actually buying?
The fund's largest China sector bet is financials — chosen for their relatively low volatility as a defensive anchor.
It is also overweight materials: the MSCI China Materials Index rose roughly 7.1% over the past month, driven by gold and copper prices, flipping from a year-to-date laggard to a leader.
This reflects a dual playbook in China: defense via financials, offense via materials and resources.
Why is biotech part of the thesis too?
Pimco has been building biotech and life-sciences positions for nearly eighteen months.
Two drivers: large pharma companies are accelerating M&A to fill their pipelines, lifting sector earnings estimates; and AI applied to healthcare could unlock treatments for more diseases.
This means → Pimco is stretching the AI logic beyond tech — if AI speeds up drug discovery, biotech becomes another outlet for the AI dividend.
When will this call be tested?
Sharef's line is straightforward: as long as Asian companies keep delivering strong earnings growth, the overweight stays.
Put simply = the bet lives or dies not on whether the AI narrative stays hot, but on quarterly earnings prints from Asia's supply-chain companies over the next few quarters.
The fund has beaten 97% of peers over three years — that track record is both the confidence behind the contrarian shift and the reason markets will watch Pimco's next moves closely.
市场有风险，内容仅供研究参考，不构成投资建议。